Anti-inflammatory activity of Terminalia paniculata bark extract against acute and chronic inflammation in rats

Talwar, Sahil; Nandakumar, Krishnadas; Nayak, Pawan G.; Bansal, Prateek; Mudgal, Jayesh; Mor, Vijay; Chamallamudi, Mallikarjuna Rao; Lobo, Richard

doi:10.1016/j.jep.2010.12.015

Cited by 66 publications

(44 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Even though the acute toxicity study was reported on 4000 mg/kg body weight dose 11 , our study supported the tolerance level even at the dose of 5000 mg/kg body weight and no toxic signs and mortality were observed. The sub acute toxicity studies did not show any significant changes in the body weight and haematological parameters in the TP extract treated groups.…”

Section: Discussionsupporting

confidence: 50%

Untitled

2016

IJPSR

View full text Add to dashboard Cite

ABSTRACT:Terminalia paniculata Roth. (TP) is a tropical tree. Traditionally, flower juice and bark of Terminalia paniculata have been used as a remedy for cholera, for the treatment of diabetes, inflamed parotid glands and in menstrual disorders. The objective of the present study is to evaluate the antidiabetic potential of Terminalia paniculata bark extract in various in-vitro models and its safety evaluation using Wistar albino rats. The in-vitro antidiabetic activity was studied using Alpha amylase, Alpha glucosidase inhibition and Glucose diffusion assay. The nitric oxide radicals scavenging activity was determined using antioxidant assay. Acute and sub acute toxicity studies were designed as per the OECD guidelines-423. TP extract shows maximum inhibition of 94.5 % on α-Amylase at 700 µg/ml and 94 % on α-Glucosidase at 1000 µg/ml. In glucose diffusion, it showed highest activity at a concentration of 1500 µg/ml. Also, it had excellent nitric oxide scavenging activity and maximum percentage inhibition of 86.12±1.01 was observed at 1500 µg/ml. Acute toxicity study supported the tolerance level even at the dose of 5000 mg/kg body weight and no toxic signs and mortality were observed. The sub acute toxicity studies did not show any significant changes in the body weight and haematological parameters in the TP extract treated groups up to the daily oral dose of 2000 mg/kg body weight. Our findings point out the promising effect of Terminalia paniculata Roth. bark as a valuable antidiabetic representative in diabetic complications. INTRODUCTION:According to WHO, 60% of the world's population depend on traditional medicine and 80% of the population in developing countries depend almost entirely on traditional medical practices, in particular, herbal medicine for their primary health care needs 1 . QUICK RESPONSE CODE

show abstract

Section: Discussionsupporting

confidence: 50%

Untitled

2016

IJPSR

View full text Add to dashboard Cite

show abstract

“…In Ayurvedic system, bark was used to treat cough, strangury, diabetes, bronchitis, leprosy and skin diseases [8]. The hepatoprotective and anti-inflammatory activity of its bark was reported [9, 10]. Previously, we have reported antidiabetic and antioxidant activity of Terminalia paniculata bark in type 1 diabetes [11].…”

Section: Introductionmentioning

confidence: 99%

In Vivo and In Vitro Antidiabetic Activity of Terminalia paniculata Bark: An Evaluation of Possible Phytoconstituents and Mechanisms for Blood Glucose Control in Diabetes

2013

View full text Add to dashboard Cite

The present study was aimed to investigate in vivo, in vitro antidiabetic activity of aqueous extract of Terminalia paniculata bark (AETPB) and characterize its possible phytoconstituents responsible for the actions. Type 2 diabetes was induced in rats by streptozotocin-nicotinamide (65 mg/kg–110 mg/kg; i.p.) administration. Oral treatment of AETPB using rat oral needle at 100 and 200 mg/kg doses significantly (P < 0.001) decreased blood glucose and glycosylated haemoglobin levels in diabetic rats than diabetic control rats. AETPB-treated diabetic rats body weight, total protein, insulin, and haemoglobin levels were increased significantly (P < 0.001) than diabetic control rats. A significant (P < 0.001) reduction of total cholesterol and triglycerides and increase in high-density lipoprotein levels were observed in type 2 diabetic rats after AETPB administration. Presence of biomarkers gallic acid, ellagic acid, catechin, and epicatechin in AETPB was confirmed in HPLC analysis. AETPB and gallic acid showed significant (P < 0.001) enhancement of glucose uptake action in presence of insulin in muscle cells than vehicle control. Also AETPB inhibited pancreatic α-amylase and α-glucosidase enzymes. In conclusion, the above actions might be responsible for the antidiabetic activity of AETPB due to presence of gallic acid and other biomarkers.

show abstract

“…It is a highly regulated biological process that enables the immune system to efficiently remove the injurious stimuli and initiate the healing process (Kular et al, 2011;Stables and Gilroy, 2011). However, uncontrolled and persistent inflammation contributes to the progression of many chronic pathological conditions, such as rheumatoid arthritis, atherosclerosis, psoriasis, inflammatory bowel disease, retinitis, multiple sclerosis (Kular et al, 2011;Talwara et al, 2011). Use of anti-inflammatory agents may, therefore, be helpful in the treatment of inflammatory disorders (Sosa et al, 2002).…”

Section: Introductionmentioning

confidence: 99%